BR112016002459A2 - Derivados de benzimidazolil-metil ureia como agonistas receptores de alx - Google Patents
Derivados de benzimidazolil-metil ureia como agonistas receptores de alxInfo
- Publication number
- BR112016002459A2 BR112016002459A2 BR112016002459A BR112016002459A BR112016002459A2 BR 112016002459 A2 BR112016002459 A2 BR 112016002459A2 BR 112016002459 A BR112016002459 A BR 112016002459A BR 112016002459 A BR112016002459 A BR 112016002459A BR 112016002459 A2 BR112016002459 A2 BR 112016002459A2
- Authority
- BR
- Brazil
- Prior art keywords
- benzimidazolyl
- urea derivatives
- methyl urea
- receptor agonists
- alx receptor
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
- C07D235/14—Radicals substituted by nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
- C07D235/16—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
- C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
Abstract
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IB2013056530 | 2013-08-09 | ||
PCT/IB2014/063795 WO2015019325A1 (en) | 2013-08-09 | 2014-08-08 | Benzimidazolyl-methyl urea derivatives as alx receptor agonists |
Publications (2)
Publication Number | Publication Date |
---|---|
BR112016002459A2 true BR112016002459A2 (pt) | 2017-08-22 |
BR112016002459A8 BR112016002459A8 (pt) | 2017-12-26 |
Family
ID=51688366
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112016002459A BR112016002459A8 (pt) | 2013-08-09 | 2014-08-08 | Derivados de benzimidazolil-metil ureia como agonistas receptores de alx |
Country Status (14)
Country | Link |
---|---|
US (1) | US9663473B2 (pt) |
EP (1) | EP3030560B1 (pt) |
JP (1) | JP6387411B2 (pt) |
KR (1) | KR20160042019A (pt) |
CN (1) | CN105473575B (pt) |
AR (1) | AR097279A1 (pt) |
AU (1) | AU2014304046B2 (pt) |
BR (1) | BR112016002459A8 (pt) |
CA (1) | CA2917954A1 (pt) |
ES (1) | ES2641172T3 (pt) |
MX (1) | MX2016001788A (pt) |
RU (1) | RU2016107974A (pt) |
TW (1) | TW201536756A (pt) |
WO (1) | WO2015019325A1 (pt) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AR096686A1 (es) | 2013-06-25 | 2016-01-27 | Actelion Pharmaceuticals Ltd | Derivados de espiro[2.4]heptano puenteados sustituidos con difluoroetil-oxazol como agonistas del receptor de alx |
JP6330038B2 (ja) | 2013-07-18 | 2018-05-23 | イドーシア ファーマシューティカルズ リミテッドIdorsia Pharmaceuticals Ltd | Alx受容体アゴニストとしてのピペラジン置換架橋スピロ[2.4]ヘプタン誘導体 |
TN2016000210A1 (en) | 2013-11-28 | 2017-10-06 | Kyorin Seiyaku Kk | Urea derivative or pharmacologically acceptable salt thereof. |
EA201792382A1 (ru) | 2015-05-27 | 2018-04-30 | Киорин Фармасютикал Ко., Лтд. | Производное мочевины или его фармакологически приемлемая соль |
EP3303284B1 (en) | 2015-05-27 | 2020-04-08 | Kyorin Pharmaceutical Co., Ltd. | Urea derivative or pharmacologically acceptable salt thereof |
MX2018004882A (es) | 2015-10-23 | 2018-08-01 | Vifor Int Ag | Inhibidores de ferroportina novedosos. |
JP6919976B2 (ja) * | 2015-11-20 | 2021-08-18 | ミングサイト ファーマシューティカルズ,インク. | 自己免疫疾患の処置 |
JP2019530678A (ja) * | 2016-09-18 | 2019-10-24 | エイチ リー モフィット キャンサー センター アンド リサーチ インスティテュート インコーポレイテッド | Yap1のoct4との相互作用を標的とするyap1阻害剤 |
JOP20180036A1 (ar) | 2017-04-18 | 2019-01-30 | Vifor Int Ag | أملاح لمثبطات فروبورتين جديدة |
US20210147405A1 (en) * | 2017-06-14 | 2021-05-20 | European Molecular Biology Laboratory | Bicyclic heteroaromatic urea or carbamate compounds for use in therapy |
CN108003048A (zh) * | 2017-12-07 | 2018-05-08 | 滨海吉尔多肽有限公司 | 一种o-甲基-苏/酪氨酸的制备方法 |
EP3762380B1 (en) | 2018-03-05 | 2021-12-15 | Bristol-Myers Squibb Company | Phenylpyrrolidinone formyl peptide 2 receptor agonists |
BR112020018642A2 (pt) | 2018-03-14 | 2020-12-29 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Composto da fórmula i, composição farmacêutica, método de tratamento de câncer em um sujeito em necessidade, método de eliminação de uma célula tumoral em um sujeito |
US20210401798A1 (en) * | 2018-10-23 | 2021-12-30 | The Brigham And Women's Hospital, Inc. | Lipoxin a4 analogs and uses thereof |
CN112341450B (zh) * | 2019-08-09 | 2022-05-17 | 成都先导药物开发股份有限公司 | 一种免疫调节剂 |
CN112341451B (zh) * | 2019-08-09 | 2022-06-17 | 成都先导药物开发股份有限公司 | 一种免疫调节剂 |
CN114644577B (zh) * | 2020-12-18 | 2023-06-27 | 新发药业有限公司 | 一种取代异腈化合物的环保制备方法 |
Family Cites Families (45)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4407746A (en) | 1981-12-14 | 1983-10-04 | G. D. Searle & Co. | Cyclohexyl and phenyl substituted enkephalins |
RU2106592C1 (ru) | 1996-07-12 | 1998-03-10 | Слипченко Николай Николаевич | Подводный спортивный пистолет |
WO1998027108A2 (en) * | 1996-12-16 | 1998-06-25 | Fujisawa Pharmaceutical Co., Ltd. | New amide compounds and their use as nitric oxide synthase inhibitors |
AU763636C (en) | 1998-01-29 | 2004-05-27 | Daiichi Asubio Pharma Co., Ltd. | 1-cycloalkyl-1,8-naphthyridin-4-one derivatives with phosphodiesterase IV inhibitory activity |
EP1387680A4 (en) | 2001-03-05 | 2010-01-13 | Transtech Pharma Inc | AGENTS TH RAPEUTICES D RIV S BENZIMIDAZOLE BASE |
FR2822827B1 (fr) | 2001-03-28 | 2003-05-16 | Sanofi Synthelabo | Nouveaux derives de n-(arylsulfonyl) beta-aminoacides comportant un groupe aminomethyle substitue, leur procede de preparation et les compositions pharmaceutiques en contenant |
DE10211770A1 (de) | 2002-03-14 | 2003-10-02 | Boehringer Ingelheim Pharma | Neue substituierte Piperidine, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung |
JP2005536187A (ja) | 2002-04-03 | 2005-12-02 | バイエル・ヘルスケア・アクチェンゲゼルシャフト | N−ホルミルペプチド受容体様1(fprl1)に関連する疾患の診断および治療 |
AU2003251828A1 (en) | 2002-07-12 | 2004-02-02 | Janssen Pharmaceutica N.V. | Naphthol, quinoline and isoquinoline-derivatives as modulators of vanilloid vr1 receptor |
PE20040804A1 (es) | 2002-12-19 | 2004-12-31 | Boehringer Ingelheim Pharma | DERIVADOS DE CARBOXAMIDAS COMO INHIBIDORES DEL FACTOR Xa |
DE602004011064T2 (de) | 2003-05-30 | 2008-12-11 | Eli Lilly And Co., Indianapolis | Antitrombotische aether |
US7141596B2 (en) | 2003-10-08 | 2006-11-28 | Incyte Corporation | Inhibitors of proteins that bind phosphorylated molecules |
CN1894580A (zh) * | 2003-11-07 | 2007-01-10 | 阿卡蒂亚药品公司 | 脂氧素受体fprl1作为一种用于鉴定能有效治疗疼痛和炎症化合物的工具 |
KR20060130064A (ko) * | 2003-11-07 | 2006-12-18 | 아카디아 파마슈티칼스 인코포레이티드 | 통증 및 염증 치료에 효과적인 화합물을 동정하기 위한도구로서의 리폭신 수용체, fprl1의 용도 |
US7371743B2 (en) | 2004-02-28 | 2008-05-13 | Boehringer Ingelheim International Gmbh | Carboxylic acid amides, the preparation thereof and their use as medicaments |
TW200538098A (en) | 2004-03-22 | 2005-12-01 | Astrazeneca Ab | Therapeutic agents |
US7453002B2 (en) | 2004-06-15 | 2008-11-18 | Bristol-Myers Squibb Company | Five-membered heterocycles useful as serine protease inhibitors |
DK1778637T3 (da) | 2004-06-29 | 2012-06-18 | Aventis Pharma Inc | FKBP-bindingssammensætninger og farmaceutisk anvendelse deraf |
EP1915345B1 (en) | 2005-08-12 | 2010-12-22 | F. Hoffmann-La Roche AG | Fluoro substituted 2-oxo azepan derivatives |
AR066379A1 (es) | 2007-05-02 | 2009-08-12 | Boehringer Ingelheim Int | Amidas de acido carboxilico su preparacion y su uso como medicamentos |
US7557221B2 (en) | 2007-08-16 | 2009-07-07 | Hoffman-La Roche Inc. | Substituted hydantoins |
AR069650A1 (es) | 2007-12-14 | 2010-02-10 | Actelion Pharmaceuticals Ltd | Derivados de aminopirazol como agonistas no peptidicos del receptor alx humano |
AU2008337097B2 (en) | 2007-12-18 | 2014-03-20 | Idorsia Pharmaceuticals Ltd | Aminotriazole derivatives as ALX agonists |
CN102083794A (zh) * | 2008-05-05 | 2011-06-01 | 安姆根有限公司 | 作为γ分泌酶调节剂的脲化合物 |
JP5476305B2 (ja) | 2008-08-07 | 2014-04-23 | 杏林製薬株式会社 | ビシクロ[2.2.2]オクチルアミン誘導体の製造方法 |
WO2010083246A1 (en) | 2009-01-15 | 2010-07-22 | Amgen Inc. | Fluoroisoquinoline substituted thiazole compounds and methods of use |
MX2011012264A (es) | 2009-05-18 | 2011-12-12 | Actelion Pharmaceuticals Ltd | Derivados spiro[2.4]heptano puenteados como agonistas del receptor de lipoxina a(alx) y/o de formil peptido tipo 2 (fprl2). |
MX342440B (es) | 2009-06-09 | 2016-09-29 | Actelion Pharmaceuticals Ltd * | Derivados fluorados de aminotriazol. |
US8674111B2 (en) | 2009-06-12 | 2014-03-18 | Actelion Pharmaceuticals Ltd. | Oxazole and thiazole derivatives as ALX receptor agonists |
CN102574843B (zh) * | 2009-10-22 | 2015-06-17 | 法博太科制药有限公司 | 抗纤维化剂的稠环类似物 |
GB201009731D0 (en) | 2010-06-10 | 2010-07-21 | Pulmagen Therapeutics Inflamma | Kinase inhibitors |
CA2814826C (en) | 2010-11-17 | 2019-02-12 | Actelion Pharmaceuticals Ltd | Bridged spiro[2.4]heptane ester derivatives |
TW201305150A (zh) | 2010-12-07 | 2013-02-01 | Actelion Pharmaceuticals Ltd | 作為脂氧素(alx)受體激動劑之羥基化胺基三唑衍生物 |
DK2649068T3 (en) | 2010-12-07 | 2014-12-08 | Actelion Pharmaceuticals Ltd | OXAZOLYL METHYLETHER DERIVATIVES AS ALX RECEPTOR AGONISTS |
TR201820873T4 (tr) | 2011-08-01 | 2019-01-21 | Hoffmann La Roche | Pd-1 ekseni bağlayıcı antagonistler ve mek inhibitörlerinin kullanıldığı kanser tedavisine yönelik yöntemler. |
KR102051687B1 (ko) | 2011-10-26 | 2019-12-17 | 알러간, 인코포레이티드 | 포르밀 펩티드 수용체 유사-1 (fprl-1) 수용체 조절자로서의 n-유레아 치환된 아미노산의 아미드 유도체 |
US8541577B2 (en) | 2011-11-10 | 2013-09-24 | Allergan, Inc. | Aryl urea derivatives as N-formyl peptide receptors like-1 (FPRL-1) receptor modulators |
US8492556B2 (en) * | 2011-11-10 | 2013-07-23 | Allergan, Inc. | 2,5-Dioxoimidazolidin-1-yl-3-phenylurea derivatives as formyl peptide receptor like-1 (FPRL-1) receptor modulators |
MA37618B1 (fr) | 2012-05-16 | 2017-08-31 | Actelion Pharmaceuticals Ltd | Dérivés pontés fluorés de spiro[2.4]heptane en tant qu'agonistes de récepteur alx |
JP6101788B2 (ja) | 2012-05-16 | 2017-03-22 | アクテリオン ファーマシューティカルズ リミテッドActelion Pharmaceuticals Ltd | ALX受容体アゴニストとしての1−(p−トリル)シクロプロピル置換架橋スピロ[2.4]ヘプタン誘導体 |
BR112015021371B1 (pt) | 2013-03-06 | 2021-04-13 | Allergan, Inc | Uso de agonistas de receptor de formil peptídeo 2 para tratar doenças inflamatórias oculares |
BR122017004256A2 (pt) | 2013-03-06 | 2019-09-10 | Allergan Inc | uso de agonistas do receptor de peptídeo formil 2 para tratar doenças dermatológicas |
AR096686A1 (es) | 2013-06-25 | 2016-01-27 | Actelion Pharmaceuticals Ltd | Derivados de espiro[2.4]heptano puenteados sustituidos con difluoroetil-oxazol como agonistas del receptor de alx |
JP6330038B2 (ja) | 2013-07-18 | 2018-05-23 | イドーシア ファーマシューティカルズ リミテッドIdorsia Pharmaceuticals Ltd | Alx受容体アゴニストとしてのピペラジン置換架橋スピロ[2.4]ヘプタン誘導体 |
WO2015042071A1 (en) | 2013-09-19 | 2015-03-26 | Allergan, Inc. | Diphenyl urea derivatives as formyl peptide receptor modulators |
-
2014
- 2014-08-07 AR ARP140102978A patent/AR097279A1/es unknown
- 2014-08-08 CN CN201480044332.8A patent/CN105473575B/zh not_active Expired - Fee Related
- 2014-08-08 CA CA2917954A patent/CA2917954A1/en not_active Abandoned
- 2014-08-08 EP EP14781943.7A patent/EP3030560B1/en not_active Not-in-force
- 2014-08-08 KR KR1020167006024A patent/KR20160042019A/ko not_active Application Discontinuation
- 2014-08-08 WO PCT/IB2014/063795 patent/WO2015019325A1/en active Application Filing
- 2014-08-08 RU RU2016107974A patent/RU2016107974A/ru unknown
- 2014-08-08 US US14/911,000 patent/US9663473B2/en not_active Expired - Fee Related
- 2014-08-08 TW TW103127343A patent/TW201536756A/zh unknown
- 2014-08-08 MX MX2016001788A patent/MX2016001788A/es unknown
- 2014-08-08 ES ES14781943.7T patent/ES2641172T3/es active Active
- 2014-08-08 AU AU2014304046A patent/AU2014304046B2/en not_active Ceased
- 2014-08-08 BR BR112016002459A patent/BR112016002459A8/pt not_active IP Right Cessation
- 2014-08-08 JP JP2016532785A patent/JP6387411B2/ja not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
EP3030560B1 (en) | 2017-06-21 |
WO2015019325A1 (en) | 2015-02-12 |
BR112016002459A8 (pt) | 2017-12-26 |
AU2014304046B2 (en) | 2018-07-05 |
EP3030560A1 (en) | 2016-06-15 |
RU2016107974A (ru) | 2017-09-15 |
US9663473B2 (en) | 2017-05-30 |
JP6387411B2 (ja) | 2018-09-05 |
TW201536756A (zh) | 2015-10-01 |
US20160200686A1 (en) | 2016-07-14 |
KR20160042019A (ko) | 2016-04-18 |
ES2641172T3 (es) | 2017-11-08 |
AU2014304046A1 (en) | 2016-03-17 |
CN105473575B (zh) | 2017-11-24 |
JP2016529251A (ja) | 2016-09-23 |
CN105473575A (zh) | 2016-04-06 |
AR097279A1 (es) | 2016-03-02 |
CA2917954A1 (en) | 2015-02-12 |
MX2016001788A (es) | 2016-05-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112016002459A2 (pt) | Derivados de benzimidazolil-metil ureia como agonistas receptores de alx | |
ECSP17016797A (es) | Indazoles sustituidos con benzilo como inhibidores de bub1 | |
CL2016001514A1 (es) | Conjugado de anticuerpo-farmaco que posee un resto quimico no peptidico, que puede ser escindido por la catepsina b; uso para la fabricacion de un medicamento util y conjugacion farmaceutica. | |
CL2016000807A1 (es) | Amino heteroarilo benzamidas como inhibidores de quinasa. | |
DOP2017000304A (es) | Nuevos derivados hidroxiácido, un proceso para su preparación y composiciones farmacéuticas que los contienen | |
NI201400150A (es) | Nuevos derivados tienopirimidina, un proceso para su preparación y composiciones farmacéuticas que los contienen. | |
CU24397B1 (es) | Derivados de piperidinil-indol como inhibidores del factor de complemento b | |
BR112015023161A8 (pt) | derivados de piridin-4-ila | |
EA201690044A1 (ru) | Модуляторы ядерного транспорта и их применение | |
CR20170590A (es) | Nuevos derivados hidroxiácido, un proceso para su preparación y composiciones farmacéuticas que los contienen | |
BR112015023417A2 (pt) | compostos heterocíclicos e seus usos | |
NI201500135A (es) | Composición farmacéutica de hidrocloruro de s-ketamina | |
CL2015002402A1 (es) | Sales de derivados de 2-amino-1-hidroxietil-8-hidroxiquinolin-2(1h)-ona que tienen actividad agonista del receptor b2 adrenergico asi como actividad antagonista del receptor muscarínico m3. | |
BR112015013463A8 (pt) | Derivados de carboxamida indol como antagonistas do receptor de p2x7 | |
SV2018005760A (es) | Derivados de aminotiazol utiles como agentes antiviricos | |
CL2016000597A1 (es) | Derivados de desoxino jirimicina y sus métodos de uso. | |
BR112015027394A2 (pt) | derivados de pirrolo[2,3-d]pirimidina como agonistas de receptor cb2 | |
BR112014030720A8 (pt) | composto, composição farmacêutica e usos de inibidores de fbx03 | |
CO7170173A2 (es) | Derivados de carbamato/urea | |
CR20160084A (es) | Derivados de amida como agonistas del receptor del ácido lisofosfatídico | |
CL2016000019A1 (es) | Compuestos derivados de dihidroxifenilo deuterado o una sal de los mismos; composición farmacéutica que los comprende y su uso para el tratamiento de trastornos mediados por neurotransmisores tales como hipotensión, trastornos del sueño, enfermedad de alzheimer y depresión. | |
BR112017015116A2 (pt) | derivados de (r)-2-metil-piperazina como moduladores do receptor cxcr3 | |
CL2017002498A1 (es) | Piridopirimidinonas y su uso como modulares del receptor nmda | |
EA201600123A1 (ru) | Производные 1-(пиперазин-1-ил)-2-([1,2,4]триазол-1-ил)этанона | |
CL2015000610A1 (es) | Derivados de isoxazolidina |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B25A | Requested transfer of rights approved |
Owner name: IDORSIA PHARMACEUTICALS LTD (CH) |
|
B25L | Entry of change of name and/or headquarter and transfer of application, patent and certificate of addition of invention: publication cancelled |
Owner name: ACTELION PHARMACEUTICALS LTD (CH) |
|
B25C | Requirement related to requested transfer of rights |
Owner name: ACTELION PHARMACEUTICALS LTD (CH) |
|
B25L | Entry of change of name and/or headquarter and transfer of application, patent and certificate of addition of invention: publication cancelled |
Owner name: ACTELION PHARMACEUTICALS LTD (CH) |
|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] | ||
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO PUBLICADO NA RPI 2472 DE 22/05/2018. |
|
B25B | Requested transfer of rights rejected |
Owner name: ACTELION PHARMACEUTICALS LTD (CH) Free format text: INDEFERIDO O PEDIDO DE TRANSFERENCIA CONTIDO NA PETICAO 870170095157 DE 07/12/2017 EMVIRTUDE DO DESPACHO PUBLICADO NA RPI NO 2489 DE 18/09/2018. |